GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » Institutional Ownership

Bio-Techne (FRA:TE1) Institutional Ownership : 78.58% (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bio-Techne's institutional ownership is 78.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bio-Techne's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bio-Techne's Float Percentage Of Total Shares Outstanding is 76.99%.


Bio-Techne Institutional Ownership Historical Data

The historical data trend for Bio-Techne's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Institutional Ownership Chart

Bio-Techne Historical Data

The historical data trend for Bio-Techne can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29
Institutional Ownership 75.75 78.60 78.75 78.51 79.38 75.32 76.80 78.24 77.71 78.58

Bio-Techne Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bio-Techne (FRA:TE1) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (FRA:TE1) Headlines

No Headlines